The Race to Build the Ultimate Menopause Health Platform

Menopause has emerged as one of the most popular areas for funding femtech investments in a very short time, with money now coming into the space fast enough to look like a genuine race. In just one example, two companies in the menopause telehealth space illustrated how the race can be run very differently. Midi Health raised around $250 million in venture capital, while Alloy Women’s Health raised just $21 million during a similar time period.

What is Causing The Current Competition in Menopause Technology?

More than 47 million women enter menopause each year. By 2030, roughly 1.2 billion women are expected to be menopausal or post menopausal. Further, the global menopause market is expected to be within the range of $15 billion to $19 billion in 2026. Employers are following the trend as well. When PwC research was reported by industry analysts, it revealed that 25% of large US employers planned to provide standalone menopause benefits by 2026 (up from just 4% in 2023). This shift, from a consumer app to an employee benefit, has been the main contributor to the growth of the sector in both the US and the UK.

Early Stage UK Startups Working in the Menopause Sector

Britain has validated its right to first ownership in this category, as menopause support as an employee benefit was launched by Peppy in London in 2018, prior to expanding support to other offerings. The company has raised a Series B round, valued at roughly €41 million, led by Albion VC. Some of their client partnerships include Clifford Chance, Santander and Vitality Health, making this offering available to many employees.

Vera Health’s ‘Stella App’

Vira Health’s Stella app provides personalised, symptom-based menopause treatment plans using cognitive behavioural therapy, pelvic floor exercises and lifestyle changes. While initially launching to consumers, the company heavily prioritised selling through employers and corporate benefits packages to scale its reach. Vira Health has raised funding from Octopus Ventures and Optum Ventures, operating with the long-term view that effective menopause support will help reduce the future risk of osteoporosis, cardiovascular disease and dementia.

The US Scale Play

The US is taking a different approach, with a growing number of FemTech companies moving beyond wellness apps towards clinician-led virtual care. Midi Health has raised more than $250 million to scale its virtual menopause and midlife healthcare model, which combines specialist clinicians with insurance-covered care. Other companies, including Elektra Health, Allara Health and Evernow, are pursuing similar clinically oriented models, combining digital platforms with medical professionals, treatment and, increasingly, insurance or employer partnerships. The shift suggests that the next stage of FemTech may depend less on wellness tracking alone and more on integrating digital convenience with clinical credibility, healthcare reimbursement and measurable outcomes.

What Makes a Meaningful Healthcare Platform for Menopause?

Consensus is forming within this space regarding what separates a meaningful healthcare platform from just a symptom tracker. It comes down to three elements: clinical (on-site, menopause-trained physicians, not generic telehealth), integration with existing systems and personalised care. When looking at the femtech funding space, the firms that raised the larger rounds this cycle were able to cite FDA clearance, clinical trials, hospital partnerships and/or physician-led care models. AI in and of itself wasn’t constructed as a differentiator in these funding rounds. AI is certainly present in pitch decks, but it’s still substantially less important than the other value proposition elements.

Where the Race Is Headed

Given that over a billion women will go through menopause in the next several years and that employers treat menopause benefits as an employment perk for the first time, there is very little chance the funding will run out. The real question is if the market consolidates around a few large, venture capital-backed menopause companies like Midi and Peppy, or if smaller, more focused companies like Alloy or Vira will show that in healthcare, things don’t have to be big to succeed. Either way, menopause has moved from the margins of health tech to one of its most closely watched races.